Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial

Sponsor
University Hospital Heidelberg
Study ID
NCT04721301
Phase
PHASE1
Status
Completed

Conditions

  • Colorectal Cancer Metastatic
  • Pancreatic Cancer Metastatic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The study will be conducted in compliance with Good Clinical Practices (ICH-GCP) and the Declaration of Helsinki, and in accordance with applicable legal and regulatory requirements, including archiving of essential documents.

Key Dates

Start date
Jan 15, 2017
Status verified
Oct 2023
Primary completion
Mar 15, 2023
Completion
Mar 15, 2023

Study Design

Enrollment
50 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Combination immunotherapy
    Treatment arm with Nivolumab, Ipilimumab and Maraviroc combination treatment

Primary Outcome Measure

Number of participants and severity of treatment-related adverse Events as assessed by CTCAE v4.0 [ Time Frame: up to 11 days ]

Related Studies